

PROLIGHT ANNOUNCES ADDITIONAL SUBSCRIPTION COMMITMENTS AND A LOCK-UP COMMITMENT FOR UPCOMING RIGHTS ISSUE OF SHARES

Prolight Diagnostics ("Prolight" or the "Company") hereby announces that additional existing shareholders and external investors have submitted subscription commitments totaling 2.9 MSEK for the upcoming rights issue of shares (the "Rights Issue") that Prolight resolved on, subject to approval by the subsequent extraordinary general meeting, on May 21, 2025. Including these new subscription commitments, the Rights Issue is now covered by subscription commitments amounting to approximately 16.2 MSEK, corresponding to approximately 16.1 percent of the Rights Issue, of which 9.9 MSEK is represented by a subscription commitment from the Company's UK-based instrument contract manufacturer ITL, corresponding to approximately 9.8 percent of the Rights Issue. In addition to its subscription commitment, ITL has undertaken not to sell or transfer any shares before September 30, 2026, under a lock-up agreement.

Subscription commitments

As previously announced, all members of the Board and management team, as well as most of the Company's employees, have committed to subscribe for shares amounting to a total of approximately SEK 3.4 million. Of this amount, the Company's CEO and Board member Ulf Bladin has committed to subscribe for shares worth SEK 1 million. In addition, ITL has committed to subscribe for shares amounting to SEK 9.9 million, with payment to be made through set-off against future costs associated with the completion of the instrument development and the production of pilot instruments to be used in the clinical performance study.

In addition to the previously communicated subscription commitments, the Company can now announce that further existing shareholders and external investors have submitted subscription commitments totaling approximately SEK 2.9 million, corresponding to approximately 2.9 percent of the Rights Issue. These existing shareholders and external investors have expressed a strong long-term interest in the Company, ahead of a period marked by significant milestones such as the whole blood study at St. Thomas' Hospital, intensified partnership discussions, and commercialization in 2026.

In total, the Rights Issue is thus covered by subscription commitments amounting to approximately SEK 16.2 million, corresponding to approximately 16.1 percent of the Rights Issue. No compensation will be paid for the submitted subscription commitments. The commitments are not secured pledged assets, restricted funds or similar arrangements.

Lock-up agreement

In addition to the subscription commitment, ITL has undertaken to the Company not to sell or transfer shares before September 30, 2026, under a lock-up agreement. The lock-up undertaking covers all shares that ITL's subscription commitment corresponds to.

Indicative timetable

June 10, 2025	Last trading day in the share with the right to participate in the Rights Issue
June 10, 2025	Extra general meeting
June 11, 2025	First trading day in the share without the right to participate in the Rights Issue
June 12, 2025	Record date for receipt of subscription rights. Shareholders registered in the share register maintained by Euroclear Sweden AB on this date will receive subscription rights for participation in the Rights Issue.
June 13, 2025	Publication of the Information Document
June 16 – June 25, 2025	Trading in subscription rights (TR) on NGM
June 16 – June 30, 2025	Subscription period in the Rights Issue
June 16 – July 16, 2025	Expected trading in paid subscribed shares (BTA) on NGM
July 2, 2025	Estimated date for announcement of issue outcome

Advisors

Mangold Fondkommission AB is financial advisor and Advokatfirman Lindahl KB is legal advisor to the Company in connection with the Rights Issue.

For further information, please contact:

Ulf Bladin, CEO

E-mail: info@prolightdx.com

Phone: +46 73 582 39 87

Company website: www.prolightdx.com

About Us

Prolight Diagnostics AB develops innovative Point-of-Care (POC) systems. These are small, portable instruments and disposable cartridges for performing in-vitro diagnostic (IVD) tests from a drop of blood.

We want to offer the foremost POC systems on the market for quick, reliable diagnosis of acute events. Our launch product will be for the measurement of troponin, to aid in the rule-in and rule-out of myocardial infarction.

The company's share is traded on the NGM Nordic SME marketplace, under the ticker PRLD.

Attachments

Prolight announces additional subscription commitments and a lock-up commitment for upcoming rights issue of shares